TLDR
- Novo Nordisk launched a multi-month subscription program for Wegovy, offering 3-, 6-, or 12-month plans for self-pay patients
- Injection prices range from $329/month (3-month) to $249/month (12-month), up to 29% below the standard $349 rate
- The Wegovy pill subscription runs $289–$249/month, versus the standard $299
- The program is live through telehealth partners Ro, WeightWatchers, and LifeMD, with Hims & Hers and Sesame coming soon
- Eli Lilly holds ~60% of the U.S. branded GLP-1 market; Novo holds ~39%
Novo Nordisk is taking direct aim at the self-pay obesity drug market with a new subscription model for its Wegovy products, hoping to close the gap on rival Eli Lilly in a market that is shifting fast.
The Danish drugmaker launched the program on Tuesday, giving eligible cash-paying patients the option to lock in a fixed monthly price across three-, six-, or 12-month plans. The longer the commitment, the lower the price.
For the Wegovy injection, that means $329 per month on a 3-month plan, $299 on a 6-month plan, and $249 on a 12-month plan. That’s compared to the standard $349 monthly price — a discount of up to 29%.
The Wegovy pill, which launched in the U.S. in January, follows a similar structure: $289, $269, or $249 per month, versus the usual $299. Patients can save up to $600 a year on the pill and $1,200 a year on the injection under the longest plan.
Prices stay flat even if a patient moves between doses, which removes one of the more confusing parts of GLP-1 pricing for out-of-pocket users.
The program is available immediately through Ro, WeightWatchers, and LifeMD. Hims & Hers, Sesame, and others are expected to be added soon. It is not yet available through Novo’s own NovoCare pharmacy, though the company said it may expand there over time.
Why Now?
The timing is no accident. Novo is under real pressure. Eli Lilly controls roughly 60% of the U.S. branded GLP-1 market, while Novo sits at about 39%. Lilly moved aggressively into direct-to-consumer sales before Novo, and its Zepbound drug has outpaced Wegovy in prescription growth.
Novo has already made internal moves to respond — replacing its CEO, cutting jobs, and installing a new head of its U.S. business. The subscription launch is the latest step in that effort.
The Wegovy pill has been pulling in patients who hadn’t previously used GLP-1 injections, which makes the window before Lilly’s oral GLP-1 arrives all the more important. Lilly’s oral obesity drug is currently under FDA review, with approval potentially expected in April.
Analysts have flagged that Novo risks being on the losing end of a price war, having already cut the Wegovy injection’s standard self-pay price from $499 to $349 back in November — a 30% drop.
Lilly’s Self-Pay Pricing for Comparison
Lilly’s Zepbound self-pay prices start at $299/month for the 2.5mg dose, $399 for 5mg, and $449 for higher doses under its “Self Pay Journey Program.”
One persistent problem the subscription is designed to address: adherence. A 2025 study estimated that around 65% of patients with obesity stop GLP-1 treatment within a year, often due to cost uncertainty and side effects.
Novo’s Ed Cinca, head of marketing and patient solutions, said patients can opt out of the subscription at any time while it’s active.
The 4mg dose of the Wegovy pill, currently priced at $149/month, will rise to $199 starting in September. The recently approved 7.2mg dose will be added to the subscription program at a later date.
Considering a new stock? You may want to see what’s on our watchlist first.
Our team at Knockout Stocks follows top-performing analysts and market-moving trends to spot potential winners early. We’ve identified five stocks gaining quiet attention that could be worth watching now. Create your free account to unlock the full report and get ongoing stock insights.Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
